News

Dr Lal Pathlabs has allotted 2,11,050 equity shares under ESOP on 06 August 2026. Pursuant to the above allotment, the paid-up equity share capital of the Company increased to Rs 1,67,84,88,200/- divided into 16,78,48,820 equity shares of Rs 10/- each.

Dr. Lal PathLabs announced that the Board of Directors of the Company at its meeting held on 24 July 2026, inter alia, have recommended the interim dividend of Rs 5 per equity Share (i.e. 50%) , subject to the approval of the shareholders.

Net profit of Dr Lal Pathlabs rose 28.02% to Rs 169.50 crore in the quarter ended June 2026 as against Rs 132.40 crore during the previous quarter ended June 2025. Sales rose 19.10% to Rs 797.70 crore in the quarter ended June 2026 as against Rs 669.80 crore during the previous quarter ended June 2025. ParticularsQuarter EndedJun. 2026Jun. 2025% Var. Sales797.70669.80 19 OPM %31.0328.71 - PBDT273.10215.70 27 PBT228.70181.10 26 NP169.50132.40 28 Powered by Capital Market - Live News

Dr. Lal PathLabs will hold a meeting of the Board of Directors of the Company on 24 July 2026.

Net profit of Dr Lal Pathlabs declined 15.18% to Rs 131.30 crore in the quarter ended March 2026 as against Rs 154.80 crore during the previous quarter ended March 2025. Sales rose 16.61% to Rs 702.70 crore in the quarter ended March 2026 as against Rs 602.60 crore during the previous quarter ended March 2025.For the full year,net profit rose 3.63% to Rs 504.80 crore in the year ended March 2026 as against Rs 487.10 crore during the previous year ended March 2025. Sales rose 12.25% to Rs 2762.90 crore in the year ended March 2026 as against Rs 2461.40 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales702.70602.60 17 2762.902461.40 12 OPM %26.5828.05 -28.3228.26 - PBDT204.70189.80 8 861.00766.60 12 PBT160.10153.40 4 699.20624.70 12 NP131.30154.80 -15 504.80487.10 4 Powered by Capital Market - Live News